ArticleACS omega2020
Description of Druglike Properties of Safranal and Its Chemistry behind Low Oral Exposure.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Targeting pathological chemokines in CVD: the role of saffron on CCL2 and CXCL8.Molecular biology reports · 2026Review
- Protective Effects of Safranal Against Spike Protein-Induced Mitochondrial Dysfunction and Inflammation in Peripheral and Central Immune Cells.Current developments in nutrition · 2026Article
- Effects ofInternational journal of molecular sciences · 2025Article
- Development of di-arylated 1,2,4-triazole-based derivatives as therapeutic agents against breast cancer: synthesis and biological evaluation.RSC medicinal chemistry · 2024Article
- ADME/PK Insights of Crocetin: A Molecule Having an Unusual Chemical Structure with Druglike Features.ACS omega · 2024Article
- Cannabidiol-Based Prodrugs: Synthesis and Bioevaluation.ACS medicinal chemistry letters · 2024Article
- Sila-CBD Derivatives as Inhibitors of Heme-Induced NLRP3 Inflammasome: Application in Hemolytic Diseases.ACS medicinal chemistry letters · 2023Article
- Mineral Content and Volatile Profiling ofFoods (Basel, Switzerland) · 2022Article
- Pharmacokinetic Assessment of Rottlerin fromACS omega · 2021Article
- Safranal protects against ischemia-induced PC12 cell injury through inhibiting oxidative stress and apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- 1,3-Cyclohexadien-1-Als: Synthesis, Reactivity and Bioactivities.Molecules (Basel, Switzerland) · 2021Review
- Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.Pharmaceutics · 2021Review
- TMPE Derived from Saffron Natural Monoterpene as Cytotoxic and Multidrug Resistance Reversing Agent in Colon Cancer Cells.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safranal, a plant secondary metabolite isolated from saffron, has been reported for several promising pharmacological properties toward the management of Alzheimer's disease. In the present study, we observe and report for the first time about several druglike attributes of safranal, such as adherence to Lipinski's rule of five; optimum lipophilicity; high permeability; low blood-to-plasma ratio; less to moderate propensity to interact with P-glycoprotein (P-gp) or breast cancer-resistant protein (BCRP) transporters; and high plasma protein binding as common to most of the marketed drugs using
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.